Valneva SE (EPA:VLA)
2.378
-0.017 (-0.71%)
Jun 3, 2026, 5:35 PM CET
Valneva SE Revenue
Valneva SE had revenue of 30.90M EUR in the quarter ending March 31, 2026, a decrease of -37.23%. This brings the company's revenue in the last twelve months to 156.33M, down -15.98% year-over-year. In the year 2025, Valneva SE had annual revenue of 174.66M with 3.00% growth.
Revenue (ttm)
156.33M
Revenue Growth
-15.98%
P/S Ratio
2.91
Revenue / Employee
231.95K
Employees
674
Market Cap
454.20M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 174.66M | 5.08M | 3.00% |
| Dec 31, 2024 | 169.58M | 15.87M | 10.32% |
| Dec 31, 2023 | 153.71M | -207.59M | -57.46% |
| Dec 31, 2022 | 361.30M | 13.22M | 3.80% |
| Dec 31, 2021 | 348.09M | 237.76M | 215.52% |
| Dec 31, 2020 | 110.32M | -15.88M | -12.58% |
| Dec 31, 2019 | 126.20M | 13.16M | 11.64% |
| Dec 31, 2018 | 113.04M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Genfit | 65.43M |
| Cellectis | 65.14M |
| Nanobiotix | 32.59M |
| MedinCell | 32.44M |
| Innate Pharma | 9.01M |
| Transgene | 7.21M |
| Inventiva | 6.76M |
| Sensorion | 5.81M |
Valneva SE News
- 7 hours ago - Valneva SE Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 14 hours ago - Valneva SE Slides: Investor presentation - Filings
- 6 days ago - Valneva to Participate at U.S. and European Investor Conferences in June - GlobeNewsWire
- 21 days ago - Valneva Q1 Earnings Call Highlights - MarketBeat
- 21 days ago - Valneva SE Earnings Call Transcript: Q1 2026 - Transcripts
- 21 days ago - Valneva SE Earnings release: Q1 2026 - Filings
- 21 days ago - Valneva SE Slides: Q1 2026 - Filings
- 21 days ago - Valneva SE Quarterly report: Q1 2026 - Filings